Adapted from Carter & Friedman (1972) Dosages of 250 mg/m2 i.v. per day for 5 days repeated every three weeks and 4.5 mg/kg i.v. per day for 10 days repeated every four weeks have been studied, but the results appear to be much the same. The lower dose therefore seems preferable. Toxicity encountered has involved chiefly the gastrointestinal tract and bone marrow. Anorexia, nausea and vomiting affects nearly all patients. The vomiting may last up to 12 hours and may be difficult to control by sedatives. These symptoms may only be seen with the first few doses and are worst during the first hour after administration of the drug. Although bone marrow suppression is usually completely reversed 1 month after start of treatment some fatalities have occurred. It is therefore necessary to proceed with care, since 'idiosyncratic' bone marrow responses may lead to severe leukopenia and thrombocytopenia.
Attempts are now being made to improve the results with DTIC by the study of analogues and by combination chemotherapy involving DTIC.
Combinations of antitumour agents are generally more effective than one might have anticipated. This is partly because the toxicities do not seem to be additive to the same degree as the antitumour effects and partly because by appropriate time and sequence of administration (often fortuitous) of the individual drugs of the combination a much greater tumour cell kill is possible. This is related, albeit very imperfectly, to differences in cell sensitivities to drugs at various stages of the cell cycle. Tannock & Frei (1971) used a combination of vincristine (cycle active), bis-chloroethyl nitrosourea (cycle independent) and DTIC (cycle active and independent) and in a preliminary study obtained 40 % objective responses in patients with metastatic melanoma.
A sensitive index of active malignant melanoma would obviously be of the greatest value. Crawhall et al. (1966) studied the significance of melanogenuria. Although it decreased witla successful use of anticancer drugs, it was unfortunately not evident until the disease was far advanced.
The following paper was also read: The basic event in malignant change may be thought of either as a change occurring in a single cell whose progeny are all potentially malignant cells or alternatively as a change occurring in a whole field of cells whose progeny are not themselves malignant but which behave in such a way that the selection, perhaps by a series of events, of one or more malignant cell lines from amongst them is more probable than from among normal cells.
One of the primary features of tumour cells is their variability. Variation in the morphology of the nuclei of tumour cells is a feature of most histological sections of tumour tissue and this is a reflection of wide variations in the chromosome content. With the exception of the Philadelphia chromosome in chronic myeloid leukaemia no constant abnormality is seen in tumours of the same histological type although there are reports ofchromosome markers and specific chromosome loss in some cases. The one feature that is, however, characteristic of all these tumours is the lack of stability of the karyotype and in some instances the selection of specific cell types can be demonstrated. It is suggested that this instability is one of the most important features of tumour cells since it is on the variation produced as a result of this instability that selective forces can operate to produce a highly invasive rapidly growing lesion. It is further suggested that such instability may be a feature of cells which, though not malignant themselves, have an unusual liability to become malignant.
Cells exposed to radiation or viruses may have a long-lasting chromosome instability and it may be this, rather than any specific abnormality, that increases the probability of malignant changes in cells exposed to these agents. In a number of inherited conditions such as Fanconi's anemia, Bloom's syndrome, xeroderma pigmentosum and ataxia telangiectasia spontaneous chromosome breakage or failure to repair induced breakage is a feature of the syndrome (German 1972). Patients with these syndromes have an unusual liability to develop malignant disease. Recent studies on a family with ataxia telangiectasia have shown that spontaneous chromosome breakage occurs and that selection of clones of chromosomally abnormal cells occurs both in vivo and in vitro in the absence of overt malignant change. It is suggested, however, that the inherent instability of t-hese cells may predispose them to undergo a malignant change. The supposedly precancerous lesions of the cervix uteri are known as carcinoma-in-situ and dysplasia. Because of differences in the use of these names, the findings from different centres show large discrepancies.
There is abundant evidence that invasive cancer is generally preceded by a stage of carcinoma-insitu or dysplasia, or both, probably in most cases for a number of years. These abnormal epithelia have many of the characteristics of cancer, and in particular they show variable chromosome aber-rations, and in some cases there is excellent evidence of the formation of clones with abnormal karyotypes. However, the distribution of modal chromosome counts has not quite the same shape as that of invasive cancer, having an even more bimodal shape with a larger proportion of counts exceeding 80, and fewer modes in the 50-10 region. There is no information about differences in tendency to progress in those with high or low modes.
Most studies of the fate of 'untreated' carcinoma-in-situ or dysplasia have required biopsy, often multiple, and this interference may have increased the proportion of regressions. It is widely thought that carcinoma-in-situ (in the strict sense) very seldom regresses spontaneously, while dysplasia sometimes or frequently does so. In the absence of biopsy, 'superficial dyskaryosis' has frequently been observed to regress, while the cytological picture of classical carcinoma-in-situ seems to be a persistent one. In many series 'dysplasia' probably represents a group with a strong tendency to spontaneous cure, and the cytological abnormality in some of these may well be simple polyploidy.
The curves from population screening studies, showing comparisons between incidence and prevalence of carcinoma-in-situ and invasive cancer, cannot at present be considered reliable because of self-selection of cases, and the effects of 'false negative' tests.
Dysplasia, carcinoma-in-situ and microcarcinoma apparently form a spectrum of changes, with an increasing probability of becoming irreversible with the development of new clones, and final evolution, in a proportion of cases, into invasive cancer.
The following papers were also read: 
